Another group reported that CSF TREM2 concentrations were elevated in Parkinson's disease subgroups with a positive tau CSF biomarker signature, but not in Parkinson's disease subgroups with a positive CSF amyloid-β signature [34]. This evidence concerns the gene MAPT and Parkinson disease.